Works matching IS 00099236 AND DT 2020 AND VI 107 AND IP 3
Results: 24
Are Regulators Talking to Each Other Across Borders?
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 481, doi. 10.1002/cpt.1761
- By:
- Publication type:
- Article
ASCPT News.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 486, doi. 10.1002/cpt.1760
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 484, doi. 10.1002/cpt.1759
- Publication type:
- Article
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 479, doi. 10.1002/cpt.1758
- Publication type:
- Article
Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 662, doi. 10.1002/cpt.1692
- By:
- Publication type:
- Article
Improving the Safety of Medicines in the European Union: From Signals to Action.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 521, doi. 10.1002/cpt.1678
- By:
- Publication type:
- Article
Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 514, doi. 10.1002/cpt.1673
- By:
- Publication type:
- Article
Evaluating the Role of Solubility in Oral Absorption of Poorly Water‐Soluble Drugs Using Physiologically‐Based Pharmacokinetic Modeling.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 650, doi. 10.1002/cpt.1672
- By:
- Publication type:
- Article
European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 541, doi. 10.1002/cpt.1669
- By:
- Publication type:
- Article
Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 639, doi. 10.1002/cpt.1668
- By:
- Publication type:
- Article
Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 628, doi. 10.1002/cpt.1666
- By:
- Publication type:
- Article
Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 617, doi. 10.1002/cpt.1665
- By:
- Publication type:
- Article
Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 607, doi. 10.1002/cpt.1662
- By:
- Publication type:
- Article
Model‐Informed Dose Selection for Xentuzumab, a Dual Insulin‐Like Growth Factor‐I/II—Neutralizing Antibody.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 597, doi. 10.1002/cpt.1648
- By:
- Publication type:
- Article
Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 588, doi. 10.1002/cpt.1645
- By:
- Publication type:
- Article
Use of Insulin and the Risk of Progression of Pancreatitis: A Population‐Based Cohort Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 580, doi. 10.1002/cpt.1644
- By:
- Publication type:
- Article
Evaluation of CYP2C19 Genotype‐Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 571, doi. 10.1002/cpt.1642
- By:
- Publication type:
- Article
Prospective CYP2C19‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 563, doi. 10.1002/cpt.1641
- By:
- Publication type:
- Article
International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 530, doi. 10.1002/cpt.1640
- By:
- Publication type:
- Article
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 492, doi. 10.1002/cpt.1639
- By:
- Publication type:
- Article
Using a Benefit–Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 495, doi. 10.1002/cpt.1589
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 471, doi. 10.1002/cpt.1519
- Publication type:
- Article
Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 553, doi. 10.1002/cpt.1634
- By:
- Publication type:
- Article
Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 3, p. 507, doi. 10.1002/cpt.1617
- By:
- Publication type:
- Article